Precision Medicine Plan 'Golden Opportunity' For Device, Diagnostic Firms
This article was originally published in The Gray Sheet
Executive Summary
A new proposed framework to realize President Obama's Precision Medicine Initiative has significant potential for device and diagnostic companies, according to NIH Director Francis Collins. He says it will give them a "competitive opportunity" to develop cheaper whole genome sequencing tests and open the door to other exciting technologies.
You may also be interested in...
US FDA: 510(k)-Exempt Class II Devices Should Withdraw Applications
In line with the 21st Century Cures Act, US FDA has finalized a list of class II devices that will no longer need pre-market notification to get to market. Also, check out our updated Cures Act implementation table.
21st Century Cures Implementation: Device Provision Updates
Dozens of reforms impacting the medtech sector were signed into law Dec. 13, 2016, in the 21st Century Cures Act. Here's a breakdown of where things stand in the implementation of key provisions.
21st Century Cures: Device Provisions
Dozens of reforms impacting the medtech sector were signed into law Dec. 13 as part of the 21st Century Cures Act. Here's a breakdown of the provisions most important to device- and diagnostic-makers.